TLT.V - Theralase Technologies Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.4800
-0.0200 (-4.00%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.5000
Open0.4900
Bid0.4750 x 0
Ask0.4800 x 0
Day's Range0.4700 - 0.4950
52 Week Range0.2000 - 0.6000
Volume536,542
Avg. Volume385,763
Market Cap69.183M
Beta (3Y Monthly)1.92
PE Ratio (TTM)N/A
EPS (TTM)-0.0300
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.38
  • ACCESSWIRE14 days ago

    Theralase Granted United States Patent to Destroy Cancer Cells with X-Ray Activated Photo Dynamic Compounds

    TORONTO, ONTRAIO / ACCESSWIRE / March 4, 2019 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations intended to safely and effectively destroy various cancers, announced today that it has been granted allowance for a United States patent to issue later this year for destroying cancer cells with X-ray activated PDCs. Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer of Theralase® and the lead inventor of the technology stated that, "In 2019, the Company plans to commence a Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study, which if successful may lead to commercialization of this technology in Canada, the United States and the European Union.

  • ACCESSWIRE18 days ago

    Theralase Named to 2019 TSX Venture 50(TM)

    TORONTO, ON / ACCESSWIRE / February 28, 2019 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated photo dynamic compounds and their associated drug formulations intended to safely and effectively destroy various cancers has been named third place on the 2019 TSX Venture 50TM in the Clean Technology & Life Sciences sector amongst all TSX Venture Exchange listed companies. The ranking is comprised of ten companies from each of five industry sectors, selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume amount.

  • ACCESSWIRE21 days ago

    Theralase Announces Appointment of New Chief Executive Officers

    TORONTO, ON / ACCESSWIRE / February 25, 2019 / Theralase Technologies Inc. (" Theralase ® " or the " Company ") ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company ...

  • ACCESSWIRE2 months ago

    Patient Five Cancer-Free Twelve Months After Single Anti-Cancer Treatment

    TORONTO, ON / ACCESSWIRE / January 31, 2019 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations intended to safely and effectively destroy various cancers reports that patient five, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study ("Study"), has demonstrated no tumour recurrence or presence of disease at the 360 day clinical and cystoscopy assessment. The Study's purpose was to evaluate TLD-1433, Theralase's lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy, primarily at 90 days and secondarily at 180 days post treatment.

  • ACCESSWIRE2 months ago

    Patient Six Cancer-Free at Nine Months After Single Anti-Cancer Treatment

    TORONTO, ON / ACCESSWIRE / January 30, 2019 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations intended to safely and effectively destroy various cancers reports that patient six, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study ("Study"), has demonstrated no tumour recurrence or presence of disease at the 270 day clinical and cystoscopy assessment. The Study's purpose was to evaluate TLD-1433, Theralase's lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy, primarily at 90 days and secondarily at 180 days post treatment.

  • ACCESSWIRE3 months ago

    Health Canada Grants ITA Approval to Commence Phase II Clinical Study

    TORONTO, ON / ACCESSWIRE / December 10, 2018 / Theralase Technologies Inc.(" Theralase® " or the " Company ") ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company ...

  • Baystreet4 months ago

    Stocks in play: Theralase Technologies Inc.

    Announced today that Theralase's Rutherrin® Photo Dynamic Therapy has been shown to increase its efficacy ...

  • ACCESSWIRE4 months ago

    Theralase(R) Granted Canadian Anti-Cancer Patent

    Theralase Granted Canadian Patent for Metal-Glycoprotein Complexes Used to Hunt Cancer Cells and When Laser Light Activated Destroy Them TORONTO, ON / ACCESSWIRE / November 15, 2018 / Theralase Technologies ...

  • ACCESSWIRE4 months ago

    Patient Five Cancer-Free After Single PDT Treatment

    Theralase Provides Update on 9 Months Post Treatment Cystoscopy Analysis TORONTO, ONTARIO / ACCESSWIRE / November 8, 2018 / Theralase Technologies Inc. (" Theralase® " or the " Company ")( ...

  • Newsfile8 months ago

    BTV Reveals Novel Cancer Treatment, Cannabis and Lithium Companies

    Vancouver, British Columbia--(Newsfile Corp. - July 26, 2018) - On BNN Sat July 28 & Sun July 29, 2018 - BTV-Business Television goes on location with four small cap companies in popular sectors. Full EpisodeBlissCo Cannabis Corp. (CSE: BLIS) — BTV shares how this CEO's distribution background will help his company profit in the rapidly expanding cannabis market. See Feature  Critical Elements Corp. (TSXV: CRE) (OTCQX: CRECF) — Electric vehicle demand spells opportunity for the key ...